Full Text View
Tabular View
No Study Results Posted
Related Studies
FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey
This study has been completed.
Study NCT00683891   Information provided by Azur Pharma, Inc
First Received: May 22, 2008   Last Updated: June 18, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Weight Gain
Sialorrhea
Additional conditions recognized in this trial
Schizophrenia
More general conditions related to this trial
Body Weight
Body Weight Changes
Mental Disorders
Mouth Diseases
Salivary Gland Diseases
Schizophrenia and Disorders with Psychotic Features
Signs and Symptoms
Stomatognathic Diseases
Interventions listed in this trial
FazaClo (clozapine, USP) ODT
Additional drug interventions recognized in this trial
Clozapine
More general drug interventions related to this trial
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
GABA Agents
GABA Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
Azur Pharma, Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services